Skip to main content
Clinical Trials/NCT00922948
NCT00922948
Withdrawn
Phase 2

A Prospective Randomized Pilot Trial of Cryoablation (CA) Versus Radio Frequency Ablation (RFA) for the Management of Small Renal Masses

St. Joseph's Healthcare Hamilton1 site in 1 countryMarch 2010
ConditionsRenal Cancers

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Renal Cancers
Sponsor
St. Joseph's Healthcare Hamilton
Locations
1
Primary Endpoint
Treatment failure rate.
Status
Withdrawn
Last Updated
9 years ago

Overview

Brief Summary

The purpose of this study is to verify the oncological efficacy and safety of cryoablation and radiofrequency ablation for the treatment of small renal tumors.

Detailed Description

By enrolling all patients treated with CA or RFA, this study will document for the first time the safety and the short and long term efficacy of CA compared to RFA as well as provide urologists and decision makers currently unavailable information on CA in Canada.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
March 2015
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Anil Kapoor

MD, FRCSC

St. Joseph's Healthcare Hamilton

Eligibility Criteria

Inclusion Criteria

  • Patients with tumors that progress in size while on a watchful waiting protocol;
  • Patients with multiple tumors;
  • Patients with a tumor in a solitary kidney;
  • Patients with poor renal function and a renal tumor;
  • Patients with significant co-morbidities that may benefit from a less invasive approach.

Exclusion Criteria

  • Large tumors \> 4.0cm;
  • Unable to have a general anesthetic;
  • Unable to comply with follow-up protocol (i.e., routine CT or MRI and a follow-up biopsy);
  • Uncorrectable bleeding diathesis;
  • Evidence of metastatic disease.

Outcomes

Primary Outcomes

Treatment failure rate.

Time Frame: Baseline, Weeks 6, 12, 24, 36, 48

Secondary Outcomes

  • Quality of life data.(Baseline, Weeks 6, 12, 24, 36 and 48)
  • Renal function - GFR of less than 60 ml per min per 1.73 m2. Serum creatinine and creatinine clearance.(Baseline, Weeks 6, 12, 24, 36 and 48)
  • Average percentage decrease in tumor size.(Baseline, Weeks 6, 12, 24, 36 and 48)
  • Intra and post-operative complications rates.(Weeks 6, 12, 24, 36 and 48)

Study Sites (1)

Loading locations...

Similar Trials